Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | completed | Phase 3 | 470 | Celgene CorporationINDUSTRY | 16 | Sep 11, 2015 | clinicaltrials |
| NCT02531841 | High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma(MATRix) | unknown | Phase 3 | 250 | University Hospital FreiburgOTHER | 1 | Aug 25, 2015 |
| clinicaltrials |
| NCT00217438 | Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma | completed | Phase 3 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00566332 | Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia | completed | Phase 3 | 414 | French Study Group on Chronic Lymphoid LeukemiaNETWORK | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01251107 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | completed | Phase 3 | 331 | Fondazione MichelangeloOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01014208 | Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma(ORCHARRD) | completed | Phase 3 | 447 | GlaxoSmithKlineINDUSTRY | 26 | Aug 7, 2015 | clinicaltrials |
| NCT01642563 | Italian Platelet Technology Assessment Study(IPTAS) | terminated | Phase 3 | 456 | Centro Nazionale SangueOTHER_GOV | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00269113 | A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma | completed | Phase 3 | 360 | Hoffmann-La RocheINDUSTRY | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00003414 | Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease | completed | Phase 3 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00398411 | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells(MoxiProph) | completed | Phase 3 | 66 | University of CologneOTHER | 1 | Jun 29, 2015 | clinicaltrials |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | terminated | Phase 3 | 48 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2015 | clinicaltrials |
| NCT00500240 | Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) | terminated | Phase 3 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT02423837 | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma(BRiF) | unknown | Phase 3 | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | withdrawn | Phase 3 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
| NCT00117598 | Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)(OPTIMAL) | completed | Phase 3 | 169 | PfizerINDUSTRY | 18 | Mar 30, 2015 | clinicaltrials |
| NCT00434161 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma | completed | Phase 3 | 281 | Swedish Orphan BiovitrumINDUSTRY | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00064038 | S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 3 | 198 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00838357 | A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).(PREDICT) | completed | Phase 3 | 118 | Genzyme, a Sanofi CompanyINDUSTRY | 7 | Mar 24, 2015 | clinicaltrials |
| NCT00002548 | SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma | completed | Phase 3 | 899 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | terminated | Phase 3 | 19 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416273 | A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 217 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416208 | Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma | completed | Phase 3 | 154 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01386398 | Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 21, 2015 | clinicaltrials |
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | terminated | Phase 3 | 800 | CTI BioPharmaINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT02336386 | CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma | unknown | Phase 3 | 100 | Beijing Chao Yang HospitalOTHER | 1 | Jan 13, 2015 | clinicaltrials |
| NCT01767714 | Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation | completed | Phase 3 | 100 | SanofiINDUSTRY | 1 | Dec 9, 2014 | clinicaltrials |
| NCT02288741 | Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy(DSMM-II) | completed | Phase 3 | 549 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Nov 11, 2014 | clinicaltrials |
| NCT01160380 | A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma | completed | Phase 3 | 50 | OncotherapeuticsINDUSTRY | 1 | Nov 6, 2014 | clinicaltrials |
| NCT02270307 | MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis(MSC-CY) | unknown | Phase 2 / Phase 3 | 40 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 21, 2014 | clinicaltrials |
| NCT02238873 | Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma | unknown | Phase 3 | 300 | Rabin Medical CenterOTHER | 1 | Oct 2, 2014 | clinicaltrials |
| NCT00059839 | Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma | completed | Phase 3 | 129 | Children's Oncology GroupNETWORK | 5 | Sep 22, 2014 | clinicaltrials |
| NCT00109031 | Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) | completed | Phase 3 | 47 | Swedish Orphan BiovitrumINDUSTRY | 0 | Sep 15, 2014 | clinicaltrials |
| NCT01609010 | A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma | completed | Phase 3 | 313 | Hoffmann-La RocheINDUSTRY | 3 | Sep 8, 2014 | clinicaltrials |
| NCT00583323 | Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET | completed | Phase 3 | 60 | Mayo ClinicOTHER | 0 | Aug 21, 2014 | clinicaltrials |
| NCT00854568 | Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL | completed | Phase 3 | 398 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT00813150 | Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma | completed | Phase 3 | 96 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Aug 15, 2014 | clinicaltrials |
| NCT01301963 | Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | terminated | Phase 3 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT00002618 | Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma | completed | Phase 3 | 242 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00002757 | TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma | completed | Phase 3 | 1,148 | Children's Oncology GroupNETWORK | 2 | Jul 24, 2014 | clinicaltrials |
| NCT00005578 | Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease | completed | Phase 3 | 219 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00139841 | Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab | completed | Phase 3 | 103 | CephalonINDUSTRY | 3 | May 9, 2014 | clinicaltrials |
| NCT00507416 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone(UPFRONT) | completed | Phase 3 | 502 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 1, 2014 | clinicaltrials |
| NCT00215943 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | terminated | Phase 3 | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 2 | Apr 17, 2014 | clinicaltrials |
| NCT00265837 | Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | completed | Phase 3 | 72 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00103610 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients | completed | Phase 3 | 298 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Mar 13, 2014 | clinicaltrials |
| NCT00103662 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients | completed | Phase 3 | 302 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Mar 13, 2014 | clinicaltrials |
| NCT00218855 | Thalidomide to Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | 363 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00438958 | Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases | completed | Phase 3 | 230 | The Canadian Blood and Marrow Transplant GroupNETWORK | 5 | Mar 5, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Sep 11, 2015source: clinicaltrials